Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 10/20 | 0.57 |
| ▸ | MGAM | O43451 | 7/20 | 0.57 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.57 |
| ▸ | SI | P14410 | 7/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490943 | 0.81 | TP53 (0.67) | TP53GAAMGAMAMY1ASI | |
| SCHEMBL29964193 | 0.80 | BCHE (0.49) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL18803150 | 0.80 | BCHE (0.49) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL1689837 | 0.79 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL13631302 | 0.78 | TP53 (0.64) | TP53GAAMGAMAMY1ASI | |
| SCHEMBL5281090 | 0.78 | GAA (0.58) | TP53GAAMGAMAMY1ASI | |
| SCHEMBL29964106 | 0.78 | BCHE (0.47) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL3045921 | 0.77 | ALDH1A1 (0.62) | NPC1SMN1; SMN2KDM4EALDH1A1CYP2C9 | |
| SCHEMBL14303694 | 0.77 | TP53 (0.59) | TP53GAAMGAMAMY1ASI | |
| SCHEMBL19933823 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | TP53 2946/4885GAA 496/4885MGAM 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.